file
Covance Blog - Sharing Innovation in Drug Development
    Publish
     
      • Blood Centers of America (BCA) and Covance Announce Agreement


        Posted by
        Published On 21 days ago

        graphic of DNA

        The Blood Centers of America (BCA) and Covance announce the renewal of their agreement to work together to advance the development of cell and gene therapies. As part of the agreement, the companies will continue to collaborate and provide sponsors easier access to development solutions, including access to research- and clinical-grade products and manufacturing.

        In addition to Covance capabilities spanning the entire development and post-approval continuum, the agreement facilitates sponsors access to:

        • Approximately 4 million healthy donors, which can be qualified according to sponsor’s requirements
        • Contract Manufacturing Services, including product collection, separation, isolation, transduction, expansion, qualification, cryopreservation, storage and distribution with facilities close to the participant
        • Lot release testing, including toxoplasma, endotoxin and mycoplasma assays
        • Clinical-grade and GMP cell and plasma-derived products
        • Research products and samples, including residual and custom samples and full-and partial-volume products
        • Collaborative consultation by subject matter experts, including on process optimization, development of protocols, Informed Consent Forms (ICFs), and participant recruitment

        The agreement reflects both organizations’ commitment to advancing the development of precision medicines. For Covance, the agreement expands upon its global expertise, capabilities and investment in the development of cell and gene therapies to help sponsors de-risk the development of precision medicines and bring therapies to patients sooner.

        For more information about the Blood Centers of America, please visit https://bca.coop/.

        Learn more information about Covance here.

      This entry was posted in Drug Development and tagged by Bookmark the permalink